For years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
24 February 2021
Clinical Pharmacology, Modeling and Simulation (CPMS), Parexel International
In October of 2020, the Food and Drug Administration (FDA) issued draft guidance for the pharmaceutical industry on The Use of Physiologically Based Pharmacokinetic Analyses — Biopharmaceutics Applications for Oral Drug Product Development, Manufacturing Changes, and Controls; you can find a copy of the draft guidance here - https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-physiologically-based-pharmacokinetic-analyses-biopharmaceutics-applications-oral-drug-product
Physiologically based pharmacokinetic (PBPK) analysis combines physiological descriptions (blood flow, tissue volume, partition coefficients, etc) and population estimates, along with the unique drug substance and drug product characteristics to model and simulate the pharmacokinetic and/or pharmacodynamic behaviors in vivo. The draft guidance offers several high-level workflows that include defining the objective of a PBPK model, model development including structure, assumptions and parameterization, model validation, and the critical step of application of the model to purpose. The guidance is only applicable for biopharmaceutics applications of orally administered drugs.
“We know that the industry standard will quickly embrace these concepts and every new orally administered drug approval will contain a rigorously developed and validated PBPK model,” notes Anita Nelson, Sr. VP of Translational Medicine that oversees CPMS at Parexel. “A review of all NDA/BLA submissions to OCP as of late 2019 showed that 50% of the new drug approvals contained PBPK modeling and analyses.1
A large portion of the guidance focuses on the concept of supporting product quality and Quality by Design using PBPK modeling. The strong predictive capabilities of properly developed and validated PBPK models make them ideal for use in formulation development, dissolution method development, derivation of product specifications, and product life-cycle management. Sponsors are advised to incorporate dissolution profiles into the PBPK model development, utilize the model to predict in vivo exposures and determine if the predictions are within 10% of the actual data.
This type of guidance is critical to groups such as Parexel’s Clinical Pharmacology, Modeling and Simulation division to offer our clients approaches that are in-line with Agency expectations as the utility of modeling and simulation moves from a bonus step to an expected one. We will need to critically review this and other guidance on the topic of PBPK modeling applications, determine where there are gaps in the approach, and, as industry-leaders, propose advancements and modifications for this ever-evolving field.
Parexel’s Clinical Pharmacology, Modeling and Simulation team encompasses approximately 33 scientists and analysts from around the globe. Our expert pharmacometricians are well poised to assist companies in the development, validation, and application of physiologically based pharmacokinetic modeling. For further information, contact Joseph Kim, PhD, RPh, VP, Clinical Pharmacology, Modeling and Simulation.
Are you using real-world evidence?
Feb 1, 2023
RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry
Jun 16, 2022
EU-CTR: Preparing for trial transition
Nov 30, 2023
Clinical pharmacology, modeling and simulation to support FIH study design
Oct 21, 2021
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Part 3: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Biosimilar Development: Are therapeutic clinical trials needed?
Nov 16, 2021
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
CNS Summit Recap: The Future is Collaborative
Nov 22, 2021
Creating EU-CTR compliant and patient-friendly lay language summaries (LLS)
Jan 26, 2022
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
New endpoints for early-stage cancer are gaining regulatory traction
Jan 28, 2022